Merck shars (MRK) rose by 3% premarket on the back of positive information about Keytruda drug

Market news

11 January 2017

Merck shars (MRK) rose by 3% premarket on the back of positive information about Keytruda drug

Shares of pharmaceutical company Merck (MRK) show a strong growth in premarket trading. The reason for rise in price of securities, as reported by CNNMoney, is the fact that on Tuesday night, the company reported that the US Food and Drug Administration (US Food and Drug Administration) is considering an accelerated approval of the drug for the treatment of lung cancer, Keytruda.

MRK shares rose to $ 61.65 (+ 2.89%).

Before the bell: S&P futures -0.09%, NASDAQ futures +0.01%

Wall Street. Stocks before the bell

Market Focus

Material posted here is solely for information purposes and reliance on this may lead to losses. Past performances are not a reliable indicator of future results. Please read our full disclaimer

Open Demo Account & Personal Page

Personal area

support@teletradepartners.com

Risk Warning: Trading in the financial markets (including trading on margin) provides a wide range of opportunities and enables investors ready to take risks to make high profits, but it carries a potentially high level of risk of loss. Therefore, prior to trading you should take into careful consideration whether such operations are suitable for you in terms of your level of knowledge and financial situation.